Skip to content
patentreply.ai
Office Action responsePricingSecurityDocs

US 12,097,207 · Application 17/547,496

US Patent 12,097,207 — assignment history and current owner

Liver Disease

Who owns US Patent 12,097,207?

US12097207 ("Liver Disease") — current assignee: LIPOCINE, INC.. Status: Active, estimated expiration November 13, 2039. 1 recorded USPTO assignment.

Based on recorded USPTO assignment data, the apparent operating assignee of US Patent 12,097,207 is LIPOCINE, INC.. Based on the most recent ownership transfer record (recorded 2021-12-10).

Patent title
Liver Disease
Application number
17/547,496
Apparent operating assignee
LIPOCINE, INC.
Patent status
Active, estimated expiration November 13, 2039
Recorded assignments
1

Recorded assignment history

ExecutedRecordedConveyanceAssignor(s)Assignee(s)Reel/frame
Oct 21, 2008Dec 10, 2021Ownership TransferNACHAEGARI, SATISH K.; BYRNE, BURKE; KIM, KILYOUNG; BAKER, JONATHAN A.; CHIDAMBARAM, NACHIAPPAN; PATEL, MAHESH V.LIPOCINE, INC.58453/311

Scrolls sideways on narrow screens

Chain of title

In 2021, NACHAEGARI, SATISH K.; BYRNE, BURKE (+4 more) assigned the patent to LIPOCINE, INC..

When does this patent expire?Look up another patent

Apparent recorded rights summary — disclaimer

This tool presents recorded assignment data from the USPTO assignment database. It does not constitute a legal opinion on ownership or title. Assignments may exist that have not been recorded. Corrective records, off-record transfers, court orders, and other events may affect actual ownership. Consult a qualified patent attorney for definitive title analysis.

The prosecution record for your AI

Application 17/547,496 · US 12,097,207

Ownership settled? Give your AI the file.

The recorded chain of title is one part of the record. PatentReply compiles the rest of US 12,097,207, from the claims as filed to the last action, for Claude, ChatGPT, Cursor, or another supported AI workspace.

One new public application a month is free. The first compile takes a few minutes.

Connect PatentReplySee the evidence

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Data sourced from public USPTO assignment records. This tool provides informational summaries and should not be relied upon as legal advice or a definitive title opinion. Always verify patent ownership independently, especially where unrecorded transfers, court orders, or other off-record events may apply.

patentreply.ai
How it worksOffice Action responsePricingDocsConnectToolsSecurityPrivacyTermsContact

© 2026 patentreply.ai

PatentReply does not train on your matters. PatentReply is not a law firm and does not practice law; it requires attorney involvement where legal judgment belongs, and you remain the practitioner of record.